|
Axsome Therapeutics, Inc. (AXSM) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Axsome Therapeutics, Inc. (AXSM) Bundle
¿Busca evaluar el valor intrínseco de Axsome Therapeutics, Inc.? Nuestra calculadora AXSM DCF integra datos del mundo real con características integrales de personalización, lo que le permite refinar sus pronósticos y mejorar sus estrategias de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | 50.0 | 270.6 | 338.3 | 422.8 | 528.5 | 660.6 | 825.8 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 440.8 | 25 | 25 | 25 | 25 | 25 |
| EBITDA | -67.2 | -99.1 | -123.6 | -174.2 | -225.0 | 79.1 | 98.8 | 123.5 | 154.4 | 193.0 |
| EBITDA, % | 100 | 100 | 100 | -348.21 | -83.15 | 23.37 | 23.37 | 23.37 | 23.37 | 23.37 |
| Depreciation | .0 | .1 | 1.2 | 5.6 | 6.8 | 212.2 | 265.2 | 331.5 | 414.4 | 518.0 |
| Depreciation, % | 100 | 100 | 100 | 11.12 | 2.53 | 62.73 | 62.73 | 62.73 | 62.73 | 62.73 |
| EBIT | -67.2 | -99.1 | -124.7 | -179.8 | -231.8 | 77.3 | 96.7 | 120.8 | 151.1 | 188.8 |
| EBIT, % | 100 | 100 | 100 | -359.33 | -85.67 | 22.87 | 22.87 | 22.87 | 22.87 | 22.87 |
| Total Cash | 220.0 | 183.9 | 86.5 | 200.8 | 386.2 | 338.3 | 422.8 | 528.5 | 660.6 | 825.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | 37.7 | 94.8 | 277.6 | 347.0 | 433.8 | 542.2 | 677.8 |
| Account Receivables, % | 100 | 100 | 100 | 75.34 | 35.04 | 82.08 | 82.08 | 82.08 | 82.08 | 82.08 |
| Inventories | .0 | .0 | .0 | 4.3 | 15.1 | 212.6 | 265.7 | 332.1 | 415.2 | 519.0 |
| Inventories, % | 100 | 100 | 100 | 8.63 | 5.59 | 62.85 | 62.85 | 62.85 | 62.85 | 62.85 |
| Accounts Payable | 10.9 | 13.5 | 13.1 | 38.6 | 40.7 | 265.3 | 331.6 | 414.6 | 518.2 | 647.7 |
| Accounts Payable, % | 100 | 100 | 100 | 77.15 | 15.03 | 78.44 | 78.44 | 78.44 | 78.44 | 78.44 |
| Capital Expenditure | .0 | .0 | -.3 | -.7 | -.6 | -1.1 | -1.4 | -1.7 | -2.1 | -2.7 |
| Capital Expenditure, % | 100 | 100 | 100 | -1.4 | -0.21508 | -0.32365 | -0.32365 | -0.32365 | -0.32365 | -0.32365 |
| Tax Rate, % | -0.40289 | -0.40289 | -0.40289 | -0.40289 | -0.40289 | -0.40289 | -0.40289 | -0.40289 | -0.40289 | -0.40289 |
| EBITAT | -68.6 | -101.5 | -129.0 | -190.0 | -232.8 | 77.3 | 96.7 | 120.8 | 151.1 | 188.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -57.6 | -98.9 | -128.6 | -201.7 | -292.4 | 132.8 | 304.3 | 380.4 | 475.5 | 594.4 |
| WACC, % | 10.09 | 10.09 | 10.09 | 10.09 | 10.09 | 10.09 | 10.09 | 10.09 | 10.09 | 10.09 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,348.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 606 | |||||||||
| Terminal Value | 7,492 | |||||||||
| Present Terminal Value | 4,632 | |||||||||
| Enterprise Value | 5,980 | |||||||||
| Net Debt | -200 | |||||||||
| Equity Value | 6,180 | |||||||||
| Diluted Shares Outstanding, MM | 45 | |||||||||
| Equity Value Per Share | 136.05 |
What You Will Receive
- Comprehensive Financial Model: Axsome Therapeutics’ actual data allows for accurate DCF valuation.
- Full Forecasting Flexibility: Modify revenue growth, profit margins, WACC, and other essential metrics.
- Real-Time Calculations: Automatic updates provide immediate results as you make adjustments.
- Professional-Grade Template: A polished Excel file crafted for top-tier valuation.
- Customizable and Versatile: Designed for adaptability, enabling repeated use for in-depth forecasts.
Key Features
- Customizable Financial Metrics: Adjust essential factors such as revenue projections, R&D spending, and operational costs.
- Instant DCF Valuation: Automatically computes intrinsic value, NPV, and additional financial metrics in real-time.
- High-Precision Accuracy: Leverages Axsome Therapeutics' actual financial data for credible valuation results.
- Effortless Scenario Analysis: Evaluate various assumptions and analyze results with ease.
- Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Axsome Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Axsome Therapeutics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Axsome Therapeutics Calculator?
- Accuracy: Utilizes real Axsome Therapeutics financial data for precise calculations.
- Flexibility: Tailored for users to easily adjust and test various inputs.
- Time-Saving: Eliminate the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
- User-Friendly: Intuitive interface suitable for users with any level of financial modeling experience.
Who Should Use Axsome Therapeutics, Inc. (AXSM)?
- Investors: Gain insights into innovative therapies and make informed investment decisions.
- Healthcare Analysts: Utilize comprehensive research and data to evaluate the company's pipeline and market potential.
- Pharmaceutical Consultants: Tailor reports and presentations on Axsome’s developments for clients in the biopharmaceutical sector.
- Medicine Enthusiasts: Explore advancements in treatment options and their implications for patient care.
- Educators and Students: Incorporate real-world case studies of Axsome Therapeutics into healthcare and business curricula.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Axsome Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Axsome Therapeutics, Inc. (AXSM).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.